1. What is TGCT? Is it cancer or non-cancerous?
TGCT is a rare, non-cancerous tumor arising from the joint lining (synovium), tendon sheath, or bursae. It is not life-threatening but can behave aggressively within the joint and cause damage if untreated. It usually occurs between ages 20–50 years but can occur at any age. It is generally a non-cancerous condition, that is, benign.
2. Why did I develop TGCT? What causes it?
You did not do anything to cause TGCT. TGCT happens due to a genetic change in certain cells of the joint lining (synovium). This change leads to overproduction of a protein called colony-stimulating factor 1 (CSF1), which attracts other cells and causes the tissue to grow abnormally inside the joint.
This is a sporadic event, meaning it is not inherited or related to lifestyle, diet, or injury.
3. In which age group does TGCT usually occur?
TGCT can occur at almost any age, but it has a typical age pattern i.e. 20 to 50 years. In children and older adults it is rare, but can still occur occasionally.
4. Is TGCT a common disease?
No, TGCT is a rare condition. It affects only a small number of people compared to other joint problems like arthritis.
5. What symptoms should I look out for?
TGCT symptoms are usually joint related and often develop slowly. Persistent joint swelling, joint pain, stiffness, reduced range of motion, warmth around joints, recurrent joint fluid buildup and joint locking are most of the common symptoms for TGCT.
6. Why am I having pain, swelling, or stiffness in my joint with TGCT?
These symptoms happen because TGCT causes abnormal tissue growth inside the joint lining (synovium).
This leads to:
- Inflammation within the joint
- Fluid buildup (joint effusion) causing swelling
- Pressure inside the joint, leading to pain
- Reduced space for normal movement, causing stiffness
Over time, this tissue can also irritate or damage cartilage and surrounding structures, which may further increase pain and limit movement. These symptoms usually develop gradually, but can worsen if the condition progresses.
7. Which joints are commonly affected by TGCT?
TGCT commonly affects the knee, hip, and ankle, and is less common in the shoulder. The localized type of TGCT more often affects the fingers, hand joints, and wrist.
8. Can TGCT affect more than one joint?
TGCT usually affects only one joint at a time (monoarticular). Involvement of multiple joints is very rare. In most patients, the condition remains limited to a single joint or tendon sheath. If more than one joint seems to be involved, your doctor may evaluate carefully to confirm the diagnosis and rule out other conditions.
9. Will this disease worsen over time if untreated?
Yes, TGCT can worsen over time if left untreated. It may lead to progressive joint damage, increased swelling, worsening pain, restricted movement, joint deformity (structural damage), and the tumor may become larger and harder to treat.
10. How is TGCT diagnosed?
TGCT is diagnosed using a combination of clinical evaluation, imaging, and biopsy.
- MRI (Magnetic Resonance Imaging) is the most important test and can strongly suggest TGCT based on its typical appearance.
- Biopsy (tissue test) may be required to confirm the diagnosis.
The final diagnosis is made by combining imaging findings with clinical assessment, and biopsy as needed.
11. Is MRI enough or is biopsy required for diagnosis of TGCT?
MRI is usually the most important test for TGCT and can strongly suggest the diagnosis based on its typical appearance. In many cases, especially when the MRI findings are classic, a biopsy may not be required. However, a biopsy (tissue test) is recommended if:
- The imaging is not typical
- There is any doubt about the diagnosis
- The location or features are unusual
In summary, MRI is often sufficient to guide diagnosis, but biopsy is used when confirmation is needed.
12. Is biopsy safe and necessary for diagnosis of TGCT?
Yes, biopsy is safe and is not always necessary but in certain cases it is done for confirmation.
13. Is there any mutation test required (like CSF1) for diagnosis of TGCT?
No, routine mutation testing is not required to diagnose TGCT.
The diagnosis is usually made based on:
- Clinical evaluation
- MRI findings
- Biopsy (if needed)
TGCT is associated with changes involving the CSF1 pathway, but testing for this is not routinely done in clinical practice.
14. How do doctors confirm it is TGCT and not something else?
Doctors confirm Tenosynovial Giant Cell Tumor by combining imaging and tissue confirmation, and by ruling out similar conditions. TGCT is confirmed by MRI findings and definitive diagnosis is made by histopathological examination.
15. What is the difference between localized and diffuse TGCT?
TGCT is broadly divided into two types: localized and diffuse, based on how much of the joint is involved.
- Localized TGCT (nodular type):
A small, well-defined lump limited to one area of the joint or tendon sheath. It is usually easier to treat with surgery and has a low chance of recurrence. - Diffuse TGCT:
A more extensive form where the abnormal tissue spreads throughout the joint lining. It can cause more swelling, pain, and joint damage, and has a higher chance of recurrence.
16. Which type of TGCT do I have and what does it mean for my treatment?
Histopathology / biopsy reports confirm which type of TGCT you have:
If it is Localized type it is a small, limited lump and treatment is typically surgical Removal (excision). It has low recurrence.
And if it is diffuse, spread throughout joints and treatment typically includes arthroscopic or open surgery, radiotherapy and targeted medications. But, it has higher chances of recurrence and needs regular follow-ups.
17. Is diffuse TGCT more serious than localized?
Yes, diffuse TGCT is more serious than localized TGCT because it behaves more aggressively inside the joint. It involves widespread synovial proliferation, has a higher recurrence rate, and a greater potential for joint damage.
18. Is TGCT also called PVNS?
Yes—TGCT was previously known as PVNS (Pigmented Villonodular Synovitis).
Today, TGCT (Tenosynovial Giant Cell Tumor) is the broader and preferred term:
- Localized TGCT → is also called nodular type
- Diffuse TGCT → was earlier referred to as PVNS
19. What are the treatment options available for TGCT?
Treatment of TGCT includes surgical excision or synovectomy. In diffuse or recurrent cases, radiotherapy or targeted therapy may be used. In localized TGCT, surgical excision is usually preferred. In some cases, if symptoms are mild and the disease is slow-growing, observation with regular follow-up may be appropriate.
20. Is surgery always required for TGCT?
In Tenosynovial Giant Cell Tumor, surgery is common—but not always required. It depends on your symptoms, type, and extent. In asymptomatic or selected cases observation or medical therapy can be considered.
21. What happens during surgery for TGCT?
During surgery for TGCT, the main goal is to remove the abnormal synovial tissue (tumor) and preserve the joint as much as possible.
22. When is surgery not possible or not recommended in TGCT?
Surgery is the main treatment for TGCT, but it may not be possible or recommended in certain situations, such as:
- When the tumor is extensive or involves critical structures, making complete removal difficult
- If surgery carries a high risk of joint damage or loss of function
- In cases of recurrent disease after multiple prior surgeries
- When the patient is not fit for surgery due to other medical conditions
In such situations, doctors may consider non-surgical options such as:
- Targeted therapy (e.g., CSF1R inhibitors)
- Radiotherapy
- Observation with regular follow-up
23. What are the risks and benefits of surgery?
The risks of surgery include recurrence, infection, stiffness, and swelling, with recurrence being the most common. The benefits include removal of the tumor, improved joint function, relief of symptoms such as pain and swelling, and prevention of further joint damage.
24. Are there medicines available to treat TGCT?
Yes medicines are available to treat TGCT but it is not first line for everyone, they are mainly used in specific conditions. Targeted therapies like CSF1R inhibitors are used in unresectable or recurrent TGCT, while surgery remains the main treatment.
25. What is targeted therapy for TGCT and how does it work?
Targeted therapy is a type of treatment that acts on specific pathways responsible for the growth of TGCT, rather than affecting all cells like traditional chemotherapy.
In TGCT, many tumor cells produce excess CSF1 (colony-stimulating factor 1), which attracts other cells and leads to abnormal tissue buildup in the joint.
Targeted medicines, called CSF1R inhibitors, work by:
- Blocking the CSF1 receptor (CSF1R);
- Reducing the recruitment of these cells;
- Helping to shrink or control the tumor.
26. Which medical therapies are commonly used for TGCT?
Some medical therapies used in TGCT include CSF1R inhibitors, of which pexidartinib is the most commonly used. Other therapies, such as imatinib and nilotinib, may be used when pexidartinib is not suitable or in recurrent cases.
27. When do doctors recommend medicines instead of surgery for TGCT?
Doctors may recommend medicines instead of surgery in certain situations, such as:
- When the tumor is not easily removable (unresectable)
- If surgery carries a high risk of joint damage or loss of function
- In cases of recurrent TGCT after previous surgeries
- When the disease is extensive (diffuse type) and difficult to completely remove
- If the patient is not fit for surgery or prefers to avoid it
28. What are the side effects of the medicines used for treating TGCT?
Common side effects may include:
- Fatigue
- Swelling (edema)
- Loss of appetite
- Nausea or diarrhea
- Hair color changes (lightening of hair)
- Changes in liver function tests
29. Can TGCT come back after treatment?
Yes, TGCT can come back after treatment especially in Diffuse TGCT type.
30. What are the chances of recurrence in my case with TGCT?
It depends on your condition and the type of disease. Diffuse TGCT has a higher recurrence rate (around 20–50%) because it spreads throughout the joint. In contrast, localized TGCT has a lower recurrence rate (around 5–15%), especially when completely removed.
31. How can recurrence of TGCT be detected early?
Recurrence of TGCT is detected early by monitoring symptoms and regular MRI follow-up, supported by clinical examination.
32. Can TGCT spread to other parts of the body?
No, TGCT does not spread to other parts of the body. However, there is a chance of recurrence, and it can spread locally within the joint, damaging surrounding tissues such as bone and cartilage.
33. How will TGCT affect my daily life?
You may experience pain, swelling, tightness, and reduced range of motion, which can make daily activities difficult. However, most people are able to live a fairly normal life with the right care.
34. Can I walk and do normal activities with TGCT?
Yes—you can usually walk and do normal daily activities with Tenosynovial Giant Cell Tumor, but it also depends on how active/severe your condition is right now.
35. Will I need physiotherapy after treatment for TGCT?
Yes—in most cases, physiotherapy is recommended after treatment for Tenosynovial Giant Cell Tumor, especially if you have had surgery.
36. How long does recovery take with TGCT?
Recovery time for Tenosynovial Giant Cell Tumor varies quite a bit depending on the type, joint involved, and treatment. Full recovery can take a bit longer in complex cases.
37. Can I exercise or play sports with TGCT?
Yes you can exercise and play sports with TGCT but you need to be selective and gradual and in accordance with your treating doctors’ instructions.
38. Will I need long-term follow-up?
Yes, long-term follow-up is needed for TGCT to maintain joint health and monitor for recurrence early.
39. How often should I get scans or check-ups with TGCT?
TGCT scans or check-ups based on type of disease, treatment received and extent of joint involvement.
40. What precautions should I take after treatment?
Avoid heavy weightlifting and high-impact activities, and take breaks from prolonged standing. Maintain a healthy routine, attend regular follow-ups, and take prescribed medications as directed. This will help in faster recovery and maintaining joint function.
41. What symptoms should make me contact my doctor immediately?
If you notice any new or worsening swelling, increase in pain, reduction in range of motion, unusual sensations, any new lump or growth near joints then contact your doctor immediately.
42. Which doctor should I consult for TGCT?
It depends on your diagnosis, treatment and surgery and condition and type of TGCT.
43. Should I see a sarcoma specialist for TGCT?
In most cases, you do not need to see a sarcoma specialist. However, in cases of diffuse TGCT, very large tumors, or multiple recurrences, consulting a sarcoma specialist may be helpful.
44. Do I need treatment at a specialized center for TGCT?
If you are diagnosed with localized TGCT, treatment by an experienced orthopedic surgeon is usually sufficient. However, in cases of diffuse TGCT, involvement of complex joints, previous failed surgery, or recurrence, treatment at a specialized center may be needed.
45. Is this condition life-threatening?
No, this condition is not life-threatening.
46. How do I cope with fear and anxiety related to TGCT?
It is completely normal to feel fear and anxiety after being diagnosed with TGCT. You can cope with it by understanding your condition clearly, maintaining regular follow-ups, seeking help, and talking to your family. Joining support groups for people with TGCT, along with maintaining healthy sleep and good nutrition, can also help.
47. Can I continue my job or daily responsibilities?
Yes, you can usually continue your job and daily responsibilities with Tenosynovial Giant Cell Tumor, but how smoothly it goes depends on the joint involved, the type of TGCT, and the stage of treatment.
48. Where can I connect with other TGCT patients for support?
We have a TGCT patients connect whats app group. where you can connect with other TGCT patients where you share your concern and experience.
This article is written by Dr. Ghazal, AIIMS, New Delhi and Dr. Pooja, AIIMS, New Delhi
